Medibact GuidesShop at Medibact

KPV Dosage: Oral and Injectable Figures, Sources and Units

KPV has no label, registered trial or human study. This page reports the mouse doses and the oral, injectable and topical vendor figures, with units per vial.

Medibact Guides · Published 2026-09-18

Illustration: Two clear glass vials, one with pale blue liquid, one empty, and a micro-spatula.
Illustration

KPV is one of the fastest-rising dosage searches on this site's map and one of the emptiest evidence files. There is no label, no registered trial, and no paper in which a human received the tripeptide. What circulates is a set of vendor figures for three routes, oral, injectable and topical, which this page reports with their dates, next to the mouse and cell concentrations the research actually used. It then works the units for the 5 mg and 10 mg vials the site's calculator uses.

KPV is lysine-proline-valine, the three C-terminal amino acids of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory activity in the gut and skin. Medibact's KPV guide covers the molecule, the mechanism and the evidence; this page stays with figures. The dosage hub lists every compound's page, and Peptifact's KPV dosage page grades the same sources from a journalist's angle.

What the sources state

Source Kind Route Figure Date read
DailyMed search, "KPV" Label search Any Zero records; no approved product 2026-09-18
ClinicalTrials.gov search, "KPV" or "Lys-Pro-Val" Registry Any Zero studies 2026-09-18
PubMed search, KPV with melanocortin, alpha-MSH, tripeptide or colitis Literature census Any 40 records; none a human administration study 2026-09-18
Dalmasso et al., Gastroenterology 2008 (PMID 18061177), full text Animal and cell study Drinking water (mice); culture 100 micromolar in drinking water for 8 days (DSS colitis) and at 48 hours (TNBS colitis); 10 nanomolar in cells 2026-09-18
Cheng et al., Science Advances 2026 (PMID 41533788) Animal study Oral conjugate (mice) Conjugate dosed at 20-fold lower than free KPV; 3.8-fold greater colonic accumulation 2026-09-18
An et al., Tissue and Cell 2026 (PMID 42585803); Lee et al., Cytotechnology 2026 (PMID 42064835) Animal and cell studies Oral (mice); culture 100 micrograms per millilitre in culture; mouse dose not stated in the abstracts 2026-09-18
Vendor page A Commonly cited Oral 250 to 500 mcg once daily; 500 mcg twice daily; 500 mcg to 1 mg two to three times daily; courses of 2 to 8 weeks 2026-09-18
Vendor page A Commonly cited Subcutaneous 250 to 500 mcg once or twice daily; 500 to 1,000 mcg twice daily short-term; 5 mg vial at 2 mL 2026-09-18
Vendor page A Commonly cited Topical Cream 0.1 to 0.5%; serum 0.5 to 1%; spray 0.1 to 0.3%; once to three times daily 2026-09-18
Vendor page B Commonly cited Subcutaneous and oral 200 to 500 mcg, often once daily by injection, once or twice daily by mouth; "no completed human dose-finding trial" 2026-09-18

The census is the finding. Every row above the vendor rows is a mouse, a dish or a nil result, and the vendor rows agree with each other because they are the same convention repeated, not because anything was measured.

Why a mouse concentration is not a dose

The research figures are concentrations, and concentrations in two different media at that. A drinking-water figure of 100 micromolar tells a reader what the mice drank, not what they absorbed or what it would be per kilogram, and the abstract does not convert it. A 10 nanomolar figure in a culture dish has no absorption, distribution or clearance attached to it at all. Neither number can be turned into a capsule or a syringe figure by any arithmetic, which is why the vendor figures cannot be traced back to the papers they sit beside. The 2026 conjugate paper makes the point from the other side: free oral KPV performed poorly enough in mice that the authors built a delivery chemistry to get twenty times less of it to the colon more effectively.

Units per dose at each research-vial size

Research-market KPV is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL, states the concentration, and converts the four figures the vendor pages use for injection, 200, 250, 500 and 1,000 mcg, into U-100 syringe units, where 100 units is 1 mL (MedlinePlus, read 2026-09-18); the site's insulin syringe units page covers the syringe reading itself. Oral capsules and topical products are not reconstituted and do not appear.

Vial Water added Concentration 200 mcg 250 mcg 500 mcg 1,000 mcg
5 mg 1 mL 5 mg/mL 4 5 10 20
5 mg 2 mL 2.5 mg/mL 8 10 20 40
5 mg 3 mL 1.67 mg/mL 12 15 30 60
10 mg 1 mL 10 mg/mL 2 2.5 5 10
10 mg 2 mL 5 mg/mL 4 5 10 20
10 mg 3 mL 3.33 mg/mL 6 7.5 15 30

The two vendor pages prepare the vial differently, one at 2.5 mg/mL and one at 5 mg/mL, so the same 500 mcg is 20 units on one and 10 on the other; the amount is identical and the concentration is the whole difference. A 5 mg vial holds ten 500 mcg amounts and twenty 250 mcg amounts whatever the water volume. The KPV calculator works any combination entered, and the site's reconstitution chart lists the same concentrations for every compound.

What the figures omit

The vendor figures carry a route and a frequency and, on one page, course lengths and a "taper"; they carry no population, no endpoint and no trial. The research figures carry a species (mice) or a cell line and a concentration, and no dose per kilogram in any abstract opened. Nothing in either set says what oral absorption in a human is, so the claim that oral doses must be three to five times higher than injected ones has no measured basis. Nothing says what a topical percentage delivers through skin. And nothing in the record, from any source, describes a human safety observation of any kind, favourable or otherwise, because no human has been studied.

What this page does not do

This page reports figures with their sources and dates and converts the injectable ones into syringe units at the site's vial sizes. It does not recommend a dose, a route, a frequency or a course for anyone, and it does not turn the vendor conventions into advice. The mixing steps and the storage of a mixed vial are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com.

Sources and dates

Opened 2026-09-18: the DailyMed SPL search API for "KPV" (zero records); the ClinicalTrials.gov v2 API for "KPV" or "Lys-Pro-Val" (zero studies); PubMed through the NCBI E-utilities for the census query (40 records) and the abstracts of PMIDs 18092346, 18061177, 19909746, 28143741, 39211778, 42585803, 42064835, 41533788, 22837805 and 41241376; the PubMed Central full text of Dalmasso 2008 (PMC2431115) for the drinking-water concentration; two vendor pages carrying dated oral, injectable and topical figures; and MedlinePlus for the U-100 definition. Corrections go to the contact page.

Frequently asked questions

What is the KPV peptide dosage?

No source can state one from evidence. There is no label (DailyMed, zero records), no registered trial (ClinicalTrials.gov, zero) and no human study in the 40 indexed papers, all checked on 2026-09-18. What exists is a set of vendor figures: 250 to 500 mcg orally once or twice a day, 200 to 500 mcg by subcutaneous injection once or twice a day, and 0.1 to 1% in creams and serums. This page reports those figures with their source category and date and does not present any of them as established.

What is the difference between oral and injectable KPV doses?

On vendor pages the oral figures are the same as or higher than the injectable ones: 250 to 500 mcg once daily up to 1 mg two to three times a day by mouth, against 200 to 500 mcg once or twice daily by injection. One page says oral doses 'need to be 3 to 5 times higher' for absorption. None of that comes from a human absorption study; the only oral KPV data are in mice, where it was given in drinking water at 100 micromolar, and the only route comparison is a 2026 mouse paper on a conjugate.

Is there a KPV peptide dosage chart?

The table on this page is one for the two vial sizes: 5 mg and 10 mg at 1, 2 and 3 mL, converting 200, 250, 500 and 1,000 mcg into syringe units. At 2.5 mg/mL (5 mg vial, 2 mL) those are 8, 10, 20 and 40 units; at 5 mg/mL they halve; at 1.67 mg/mL (5 mg vial, 3 mL) they are 12, 15, 30 and 60. Oral capsules and creams are not on the chart because no reconstitution applies to them.

What is the KPV protocol on vendor pages?

The pages read on 2026-09-18 describe courses of 4 to 8 weeks orally and 4 to 6 weeks by injection, with a higher short block of 500 mcg to 1 mg twice daily for one to four weeks 'then taper', and topical use once or twice daily. Every one of those is a vendor's own structure. No trial of any length exists, so the course lengths have no source beyond the pages that state them, and this page does not present them as a plan.

What doses did the KPV studies actually use?

Concentrations, not doses. Dalmasso 2008 put 100 micromolar KPV in the drinking water of colitis mice for 8 days and stimulated cultured cells at 10 nanomolar. Later papers loaded it into nanoparticles for the colon, tested 100 micrograms per millilitre on liver and fat cells, and in 2026 gave mice an oral conjugate at one twentieth of the free-peptide dose. A micromolar concentration in water and a nanomolar one in a dish do not convert to a human milligram figure, which is why none is offered here.

How many units is 500 mcg of KPV?

At 2.5 mg/mL, which a 5 mg vial reaches with 2 mL of water, 500 mcg is 0.2 mL, or 20 units on a U-100 syringe. At 5 mg/mL (5 mg vial with 1 mL, or 10 mg vial with 2 mL) it is 10 units; at 10 mg/mL it is 5 units; at 1.67 mg/mL it is 30 units. Vendor pages use both the 2 mL and the 1 mL preparations, so the same 500 mcg appears as 20 units on one page and 10 on another; the concentration explains the difference.